Clinical trial

Comparative Study of Human Immunodeficiency Virus Negative Host Talaromyces Between Voriconazole and Amphotericin Sequential Itraconazole Therapy

NCT03827278

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2018-12-30

PhaseNA

Study timeline

Study start (actual)2018-12-30Date precision: day

Registry last updated2019-02-05

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Talaromyces in Human Immunodeficiency Virus Negativeunresolved

To Compare Voriconazole and Amphotericin Sequential Itraconazole Therapyunresolved

To Dynamically Monitor the Anti-Interferon-γ Autoantibodiesunresolved

Interventions

VoriconazoleDRUG · verified · RxNorm: voriconazole

Sponsors & collaborators

Guangxi Medical Universitylead sponsor

First Affiliated Hospital of Guangxi Medical Universitycollaborator

Second Affiliated Hospital of Guangzhou Medical Universitycollaborator

The Fourth People's Hospital of Nanningcollaborator

Guilin Medical Collegecollaborator

Nanning Second People's Hospitalcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03827278 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.